Search Results Search Sort by RelevanceMost Recent Podcast May 2019 Ethics Talk: When and How Should ECMO Be Initiated and Removed? When should ECMO be started and stopped? This month’s Ethics Talk explores ethical challenges of ECMO use in end-of-life care. Case and Commentary Oct 2019 How Should Decision Science Inform Scarce Blood Product Allocation? Eric Kersjes, MD and Lauren B. Smith, MD Decision aids could help clinicians know when to request ethics consultation or re-evaluate blood product usage in a specific patient care situation. AMA J Ethics. 2019;21(10):E852-857. doi: 10.1001/amajethics.2019.852. Case and Commentary Apr 2016 Is Proxy Consent for an Invasive Procedure on a Patient with Intellectual Disabilities Ethically Sufficient? Commentary 1 Stephen Corey, MD and Peter Bulova, MD Women with intellectual disabilities should not be sedated for a pap smear without their assent, and the test’s risks and benefits should be weighed. AMA J Ethics. 2016;18(4):373-378. doi: 10.1001/journalofethics.2016.18.4.ecas3-1604. Case and Commentary Dec 2019 How Should Physicians Respond When They Learn Patients Are Using Unapproved Gene Editing Interventions? Carolyn Riley Chapman, PhD, MS and Arthur L. Caplan, PhD Responding to patients violating US health commerce regulations can be critical when they buy and use unproven interventions. AMA J Ethics. 2019;21(12):E1021-1028. doi: 10.1001/amajethics.2019.1021. Case and Commentary Apr 2016 Is Proxy Consent for an Invasive Procedure on a Patient with Intellectual Disabilities Ethically Sufficient? Commentary 2 Sonya Charles, PhD Women with intellectual disabilities should not be sedated for a pap smear without their assent, and the test’s risks and benefits should be weighed. AMA J Ethics. 2016;18(4):379-383. doi: 10.1001/journalofethics.2016.18.4.ecas3-1604. Case and Commentary Jul 2019 Should Dialysis Be Stopped for an Unrepresented Patient With Metastatic Cancer? Adira Hulkower, JD, MS, Sarah Garijo-Garde, and Lauren S. Flicker, JD, MBE Legal inconsistencies and variation in end-of-life options generate disparities in care for unrepresented patients. AMA J Ethics. 2019;21(7):E575-581. doi: 10.1001/amajethics.2019.575. Case and Commentary Jul 2019 How Should Clinicians Navigate Decision Making for Unrepresented Patients? Timothy M. Dempsey, MD, MPH and Erin Sullivan DeMartino, MD A deliberative approach to responding to needs and vulnerabilities of unrepresented patients can help make the most of having too little information. AMA J Ethics. 2019;21(7):E559-565. doi: 10.1001/amajethics.2019.559. Health Law Jul 2019 Regional Unrepresented Patient Advocacy Committee as an Alternative for Decision Making Lisa K. Anderson-Shaw, DrPH, MA, MSN, ANP-BC A UPAC is an alternative to engaging a guardianship court appointment process or to using physicians or ethics committees as decision makers. AMA J Ethics. 2019;21(7):E594-599. doi: 10.1001/amajethics.2019.594. AMA Code Says Jul 2019 AMA Code of Medical Ethics’ Opinions Related to Unrepresented Patients Danielle Hahn Chaet, MSB The AMA Code of Medical Ethics discusses situations in which a surrogate is needed but not available to make health care decisions for a patient. AMA J Ethics. 2019;21(7):E600-602. doi: 10.1001/amajethics.2019.600. Health Law Jul 2019 Who Makes Decisions for Incapacitated Patients Who Have No Surrogate or Advance Directive? Scott J. Schweikart, JD, MBE Physicians, committees, and guardians all make decisions for unrepresented patients in the US. This article considers a “tiered” approach as an alternative. AMA J Ethics. 2019;21(7):E587-593. doi: 10.1001/amajethics.2019.587. Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last »
Podcast May 2019 Ethics Talk: When and How Should ECMO Be Initiated and Removed? When should ECMO be started and stopped? This month’s Ethics Talk explores ethical challenges of ECMO use in end-of-life care.
Case and Commentary Oct 2019 How Should Decision Science Inform Scarce Blood Product Allocation? Eric Kersjes, MD and Lauren B. Smith, MD Decision aids could help clinicians know when to request ethics consultation or re-evaluate blood product usage in a specific patient care situation. AMA J Ethics. 2019;21(10):E852-857. doi: 10.1001/amajethics.2019.852.
Case and Commentary Apr 2016 Is Proxy Consent for an Invasive Procedure on a Patient with Intellectual Disabilities Ethically Sufficient? Commentary 1 Stephen Corey, MD and Peter Bulova, MD Women with intellectual disabilities should not be sedated for a pap smear without their assent, and the test’s risks and benefits should be weighed. AMA J Ethics. 2016;18(4):373-378. doi: 10.1001/journalofethics.2016.18.4.ecas3-1604.
Case and Commentary Dec 2019 How Should Physicians Respond When They Learn Patients Are Using Unapproved Gene Editing Interventions? Carolyn Riley Chapman, PhD, MS and Arthur L. Caplan, PhD Responding to patients violating US health commerce regulations can be critical when they buy and use unproven interventions. AMA J Ethics. 2019;21(12):E1021-1028. doi: 10.1001/amajethics.2019.1021.
Case and Commentary Apr 2016 Is Proxy Consent for an Invasive Procedure on a Patient with Intellectual Disabilities Ethically Sufficient? Commentary 2 Sonya Charles, PhD Women with intellectual disabilities should not be sedated for a pap smear without their assent, and the test’s risks and benefits should be weighed. AMA J Ethics. 2016;18(4):379-383. doi: 10.1001/journalofethics.2016.18.4.ecas3-1604.
Case and Commentary Jul 2019 Should Dialysis Be Stopped for an Unrepresented Patient With Metastatic Cancer? Adira Hulkower, JD, MS, Sarah Garijo-Garde, and Lauren S. Flicker, JD, MBE Legal inconsistencies and variation in end-of-life options generate disparities in care for unrepresented patients. AMA J Ethics. 2019;21(7):E575-581. doi: 10.1001/amajethics.2019.575.
Case and Commentary Jul 2019 How Should Clinicians Navigate Decision Making for Unrepresented Patients? Timothy M. Dempsey, MD, MPH and Erin Sullivan DeMartino, MD A deliberative approach to responding to needs and vulnerabilities of unrepresented patients can help make the most of having too little information. AMA J Ethics. 2019;21(7):E559-565. doi: 10.1001/amajethics.2019.559.
Health Law Jul 2019 Regional Unrepresented Patient Advocacy Committee as an Alternative for Decision Making Lisa K. Anderson-Shaw, DrPH, MA, MSN, ANP-BC A UPAC is an alternative to engaging a guardianship court appointment process or to using physicians or ethics committees as decision makers. AMA J Ethics. 2019;21(7):E594-599. doi: 10.1001/amajethics.2019.594.
AMA Code Says Jul 2019 AMA Code of Medical Ethics’ Opinions Related to Unrepresented Patients Danielle Hahn Chaet, MSB The AMA Code of Medical Ethics discusses situations in which a surrogate is needed but not available to make health care decisions for a patient. AMA J Ethics. 2019;21(7):E600-602. doi: 10.1001/amajethics.2019.600.
Health Law Jul 2019 Who Makes Decisions for Incapacitated Patients Who Have No Surrogate or Advance Directive? Scott J. Schweikart, JD, MBE Physicians, committees, and guardians all make decisions for unrepresented patients in the US. This article considers a “tiered” approach as an alternative. AMA J Ethics. 2019;21(7):E587-593. doi: 10.1001/amajethics.2019.587.